What is Endostim?
EndoStim is dedicated to pioneering a neurostimulation treatment system designed to offer long-term control for patients suffering from drug-refractory GERD. The EndoStim System delivers mild electrical signals to the lower esophageal sphincter muscle, aiming to alleviate symptoms and improve the quality of life for millions affected by this condition. While currently limited to investigational use in the US, the company's focus on a significant unmet medical need positions it within the competitive landscape of advanced gastrointestinal therapies.
How much funding has Endostim raised?
Endostim has raised a total of $94.6M across 12 funding rounds:
Private Equity
$5.5M
Private Equity
$14.1M
Series C
$9.1M
Unspecified
$11.2M
Private Equity
$6.4M
Private Equity
$2.5M
Series D
$25M
Private Equity
$12.1M
Private Equity (2011): $5.5M, investors not publicly disclosed
Private Equity (2012): $14.1M, investors not publicly disclosed
Series C (2013): $9.1M led by Prolog Ventures and Billiken Angels Network
Unspecified (2013): $11.2M, investors not publicly disclosed
Private Equity (2014): $6.4M, investors not publicly disclosed
Private Equity (2015): $2.5M, investors not publicly disclosed
Series D (2016): $25M with participation from Wellington Partners, Endeavour Vision, Sante Ventures, and Gimv
Private Equity (2017): $12.1M, investors not publicly disclosed
Key Investors in Endostim
Prolog Ventures
Prolog Ventures is a venture capital firm that invests in startups dedicated to promoting healthy living and sustainability. Their portfolio includes companies that offer products such as sparkling water made with real fruit, healthy meal options, and innovative agricultural solutions. They also support services like mobile massage therapy aimed at providing non-opioid pain relief. The firm targets businesses that align with their mission of fostering a healthier world.
Sante Ventures
Sant is a privately held company that invests in innovative healthcare enterprises, focusing on Biotech, Medtech, and Healthtech sectors. The company manages over 1 billion in capital to improve patient health outcomes through strategic investments in emerging technologies. Additionally, Sant Capital employs MindRank, a proprietary data science and machine learning software, to identify investment opportunities in mispriced publicly traded securities. Their target clients are visionary entrepreneurs and innovative companies in the healthcare industry.
Wellington Partners
Wellington Partners is a leading European venture capital firm that invests in early- and growth-stage life science companies across various sectors, including therapeutics, medical devices, diagnostics, digital health, and industrial biotechnology. Since its inception in 1998, the firm has supported outstanding entrepreneurs in transforming their innovative ideas into successful businesses. With a highly experienced team and a diversified portfolio, Wellington Partners aims to unlock the potential of breakthrough technologies in the health sector. The firm primarily targets life science entrepreneurs from Germany, Europe, and beyond, helping them become global leaders in their fields.
What's next for Endostim?
With the recent influx of capital, Endostim is poised to accelerate its development and regulatory pathways. The company's strategic financing suggests a focus on advancing clinical trials, potentially seeking US market approval, and scaling its operations to meet anticipated demand. Continued investment in this area of medical technology highlights the growing interest in non-pharmacological solutions for chronic conditions, positioning Endostim for potential market leadership in advanced GERD treatment.
See full Endostim company page
